of genetic modifiers in an orthologous rat model of ARPKD.
polycystic kidney disease; genetic modifiers CURRENT CONVENTION GENERALLY restricts the use of the term "polycystic kidney disease" (PKD) to two genetically distinct conditions: autosomal recessive PKD (ARPKD) (OMIM 263200) and autosomal dominant PKD (ADPKD) (OMIM 173900; 173910). ARPKD occurs less frequently than ADPKD with an incidence of ϳ1/20,000 live births (compared with 1/400 for ADPKD) (50) , and the phenotypic manifestations are usually far more severe. Approximately 30% of ARPKD cases result in neonatal death, and for patients surviving the neonatal period, ϳ50% of affected individuals progress to end-stage renal disease within the first decade of life (5, 42) . For patients surviving the perinatal period, a wide range of associated morbidities can develop, including systemic hypertension, renal failure, portal hypertension, and renal and hepatic fibrosis (6, 8) . Despite this phenotypic variability, genetic linkage studies indicate that mutations at a single locus are responsible for all phenotypes of ARPKD (15) .
ARPKD in humans is caused by mutations in a single gene, PKHD1 (polycystic kidney and hepatic disease 1), which encodes a large transmembrane receptor-like protein, called fibrocystin or polyductin, mapping to human chromosome 6p12 (40) . Hundreds of different PKHD1 mutations have been described with alleles ranging from amino acid substitutions to protein frameshifts and resultant truncations (2, 3) . Genotypephenotype correlations are limited but have been observed between the type of PKHD1 mutation (i.e., truncating) and the severity of the PKD phenotype (2) . Genetic heterogeneity of the PKHD1 mutation can explain much of the phenotypic variability, but it is also likely that genetic modifiers influence the manifestation of the disease (18, 41) . Identifying genetic modifiers of ARPKD in humans has remained difficult due to genetic heterogeneity and environmental variability; therefore alternative methods are necessary to investigate modifiers of this disease.
Rodent models serve as a powerful tool to study PKD because they allow for extensive experimental control of both genetic and environmental variables. A number of murine models of ARPKD have been described (16, 24, 34, 37, 38) . These models have been used to successfully identify some genetic modifiers of PKD (4, 35, 48) ; however, these previously identified genetic modifiers account for only a small percentage of the total genetic variability of the phenotype (35) . Thus, there is a need to pursue additional orthologous models of ARPKD that can be utilized to map genetic modifiers of this disease. The PCK (polycystic kidney) rat serves as a particularly useful rodent model of PKD because it shares the same causative gene with humans affected by ARPKD. The PCK strain was developed by generations of inbreeding SD (Sprague-Dawley) rats carrying a spontaneous mutation in the Pkhd1 gene. PCK rats develop both renal and hepatic (biliary) cysts that closely mimic the human disease phenotype. Cysts in both organs are apparent during the first week of life and increase in size and number with age (24) . Renal cysts are restricted predominantly to collecting tubule segments, a pattern closely resembling the human ARPKD renal phenotype (24, 30) . As the only orthologous rodent model of ARPKD that mimics the human phenotype, the PCK rat is a powerful tool for investigating ARPKD genetic modifiers and pathophysiology of the disease. These findings may be translated into future therapeutic interventions for humans.
To facilitate the search for genetic modifiers that modulate ARPKD disease progression and severity, we sought to generate a congenic rat model that carries the PCK Pkhd1 mutation but changes the onset and/or progression of ARPKD. In the present study we transferred the Pkhd1 mutation from the PCK rat onto the genetic background of the FHH (Fawn-Hooded Hypertensive) rat. This newly developed strain, called FHH.Pkhd1, showed significant amelioration of renal disease but little to no difference in onset or degree of biliary abnormalities. At 6 mo of age, the disease-resistant FHH.Pkhd1 rats had nearly normal kidney weights and dramatically reduced renal cyst formation compared with PCK rats. Renal function, as assessed by serum creatinine and blood urea nitrogen (BUN), was also improved in FHH.Pkhd1 compared with PCK. These observed phenotypic improvements demonstrate that certain genetic elements of the FHH genome protect FHH.Pkhd1 rats from the development of renal manifestations of ARPKD. To define genes and pathways that are associated with renal cystogenesis in our model, we investigated transcriptional changes in kidneys from PCK, SD, FHH, and FHH.Pkhd1 rats by microarray analysis. The transcriptional profile of PCK kidneys closely resembles the profile of previously described PKD kidneys, whereas FHH.Pkhd1 kidneys do not share common markers of the disease. Furthermore, genes that we found to be misregulated to a similar degree in both PCK and FHH.Pkhd1 may provide insight into molecules affected by the Pkhd1 mutation itself and independent of disease progression. Phenotypic analysis of the FHH.Pkhd1 strain revealed that genetic background clearly influences renal manifestations of ARPKD. This strain provides a novel model for investigating the genetic modifiers and pathophysiology of ARPKD.
MATERIALS AND METHODS
Development of the FHH.Pkhd1 congenic strain. Rats were housed in the Biomedical Resource Center of the Medical College of Wisconsin, an American Association for the Accreditation of Laboratory Animal Care-approved facility. All protocols used in these studies were approved by the local Institution Animal Care and Use Committee. Rats were fed 5LOD diet (Purina, Jefferson, WI) for the duration of all experiments.
A FHH male was crossed with a PCK female, and the male progeny were backcrossed to FHH females for five generations by markerassisted breeding. In each generation, males were genotyped by fluorescent genotyping as previously described (33) for three markers within the Pkhd1 gene and an additional 98 markers evenly spaced throughout the genome. Males and females from the N5 generation were intercrossed, and pups homozygous for the Phkd1 mutated allele were selected for establishing the FHH.Phkd1 [FHH.PCK-(D9Rat35-D9Rat70)/Mcwi, RGD ID 5147594] colony, which provided the animals for characterization.
To examine the level of contamination of the genome in FHH.Pkhd1, we genotyped both the FHH and FHH.Pkhd1 strains using the Affymetrix customized single nucleotide polymorphism (SNP) chip (803,848 SNPs) according to the manufacturer's recommendations (Affymetrix, Santa Clara, CA). In brief, genomic DNA was digested and ligated to universal adaptors before subsequent PCR amplification. PCR products were purified and fragmented, and the fragmented products were end-labeled with biotin and hybridized to the array. The data files obtained from the Affymetrix customized SNP chip were analyzed by Affymetrix Power Tools (APT) in apt-1.12.0 version (Affymetrix) . The genotype calling algorithm used in this study, BRLMM-P, has been previously described by Affymetrix (1) . Each array included 803,848 polymorphic SNPs randomly located throughout the genome excluding chromosome Y. The overall success rate of SNP genotypes was 99.1%, with a median inter-SNP distance of 1,008 bp and a mean inter-SNP distance of 3,378 bp. If a SNP genotype could not be determined, the SNP was recognized as "no call" and was excluded from the present study.
From a total of 800,478 SNPs analyzed genome wide, and excluding the congenic region, we found only 0.30% of the genome containing the non-FHH allele after five generations of marker assisted backcross, which is less than expected after eight generations of backcrossing with random recombination (0.39%).
Blood pressure measurement. All phenotypic analysis was performed on male rat strains carrying the Pkhd1 mutation (PCK and FHH.Pkhd1) as well as the respective genetic control strains (SD for PCK and FHH for FHH.Pkhd1). At 9 wk of age rats were anesthetized with 2% isoflurane, and a blood pressure transmitter (DSI, T11PA-C40) was surgically implanted subcutaneously with the catheter tip secured in the abdominal aorta via the femoral artery. After a 6 day recovery period, blood pressure was measured by radio telemetry in conscious freely moving animals one day each week for 3 h per day. Mean arterial pressure was calculated and averaged over the recording segment.
In vivo proteinuria. At 15, 24, and 27 wk of age, rats were placed in metabolic cages (Lab Products, Seaford, DE) and allowed to acclimate for 24 h followed by a 24 h urine collection. Urine protein concentration was measured using the Coomassie Plus-Better Bradford Assay kit (Pierce, Rockford, IL).
Plasma and organ analysis. At the end of the study, 27 wk old rats were anesthetized with isoflurane, and 2 ml of blood was drawn from the abdominal aorta, stored in heparinized vials and spun at 5,000 RPM to separate red blood cells from plasma. The plasma was collected and analyzed for creatinine and BUN by the ACE Autoanalyzer Clinical Chemistry System (Alfa Wassermann, West Caldwell, NJ). Following blood collection, kidneys and livers were collected, weighed, fixed in 10% buffered formalin (Sigma-Aldrich), embedded in paraffin, and sectioned for histological and immunohistological (IHC) analysis.
Kidneys and livers from all four genotypes were also removed from animals at postnatal day 30, 60, 90, or 120 and fixed in 10% buffered formalin and embedded in paraffin. The site of renal cystic lesions was determined by IHC using a collecting tubule-specific lectin and/or antibody.(10) Biotinylated dolichous biflorus agglutinin (DBA) specifically binds to rat collecting tubules, and a monoclonal antibody to the cell surface of collecting tubule principal cells, F-13, was used to verify DBA specificity. Renal cystic lesions in both PCK and FHH.Pkhd1 were primarily of collecting tubule origin.
Collecting tubule cyst growth was assessed using a cyst index as described previously (44) . Briefly, a collecting tubule cystic index (CT-CI) was developing by measuring the size of renal cystic lesions in male PCK rats at 30 day intervals starting at day 30. We stained five to ten 8 M sections, spaced 160 M apart, with hematoxylin, and renal cysts from each section were measured (the longest axis) to determine the number and size of renal cystic lesions characteristic of PCK animals of that particular age.
Microarray expression analysis. Both kidneys were harvested from SD, FHH, PCK, FHH.Pkhd1 male rats at 30 days of age (6 animals for each strain). The kidneys were bisected and stored in RNAlater at 4°C for 24 h. RNA was extracted using TRIzol (Invitrogen, Carlsbad, CA) method according to manufacturer's instructions. RNA from each strain was pooled, reverse transcribed, and hybridized to three Affymetrix Rat 230 arrays (Affymetrix) . Image data were quantified with Affymetrix Expression Console Software and normalized with Robust Multichip Analysis (http://www.bioconductor.org/) to determine signal log ratios. ANOVA was conducted, and P values were determined using Partek Genomics Suite version 6.2 for all possible pairwise comparisons. To capture the most reliable data, limit the length of gene lists, and facilitate focused pathway analyses, differentially expressed probe sets were defined as those possessing a false discovery rate (FDR) of Ͻ0.05 between the compared groups for all analyses. The FDR was set to Ͻ0.05 to ensure 95% of the genes in the list are expected to be true positive under the model assumption (only Ͻ5% of chance being false positive, P Ͻ 0.05). This threshold was set to obtain a reasonable length of gene lists for follow-up analysis. The microarray data has been submitted to the Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) under the accession number GSE33056.
To test the reliability of the microarray data, we performed quantitative PCR (qPCR) using primers designed over selected Affymetrix probe sequences. The same RNA used in the microarray experiments was reverse transcribed using the SuperScript III reverse transcription kit according to the manufacturer's instructions (Invitrogen). Unique primers for qPCR were designed directly over the following microarray probe sequences; 1371970_AT (Fam111a), 1368224_AT (Serpina3n), 1391864_AT (Enpp6), 1369663_AT (Ephx2), 1391262_AT (LOC690251), 1397688_AT (Pcdh9), 1379420_AT (RGD1565002), and 1383783_AT (Pcdh9). Primer sequences are listed in Table 1 . qPCR reactions were performed using GoTaq qPCR mastermix (Promega, Madison, WI), and amplification cycling was done on the 7900 HT thermocycler (Applied Biosystems) as follows: 95°C for 10:00, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min (acquisition). The target qPCR cycle threshold (Ct) values were compared with GAPDH Ct values as an internal reference. Delta Ct values were compared between SD, PCK, FHH, and FHH.Pkdh1 by a one-way ANOVA followed by a Bonferroni post hoc test using Prism Graph Pad software (La Jolla, CA). The results of the qPCR verified the microarray results (i.e., significantly increased fold change in the microarray was also significantly increased by qPCR, or no significant difference by microarray was also found to be not significantly different by qPCR) ( Table 2 ) for a majority (12 out of 16) of the PCR reactions, demonstrating the reliability of the microarray technique. qPCR data are presented as fold changes between PCK and SD and between FHH and FHH.Pkhd1.
Statistical analysis.
Data is presented as mean Ϯ SE. We analyzed data by Student's t-test, one-way ANOVA, or two-way repeatedmeasures ANOVA followed by the Holm-Sidak multiple comparison test using the Sigma Plot 11.0 software. Data failing normality or equal variance were analyzed by a nonparametric ANOVA on Ranks.
RESULTS

Morphometric and histological evaluation of FHH.Pkhd1 kidneys and livers.
The body weights of FHH.Pkhd1 animals were not significantly different from FHH controls, and PCK body weights were not significantly different from SD controls (data not shown). However, kidneys, from 27 wk old FHH. Pkhd1 rats were significantly smaller in weight compared with those from PCK rats (2.118 g Ϯ 0.199 vs. 5.798 g Ϯ 0.380, P Ͻ 0.001), and FHH.Pkhd1 kidneys were not significantly enlarged compared with noncystic SD or FHH kidneys (Fig. 1A) . Macroscopically, PCK kidneys appeared enlarged and severely mottled whereas FHH.Pkhd1 kidneys resembled SD and FHH kidneys. The smaller kidney size of the FHH.Pkhd1 rat kidneys appears to be due to attenuated renal cyst formation. Histolog- Table 1 
. Primer sequences designed over nine different Affymetrix probes used for qPCR
CCACGGTTCACCATCAATTT TCATCAAACACCCCTCACAA GAPDH primers were used as an internal reference. Sequences are listed in 5= to 3= orientation for both forward and reverse primers. ical analysis revealed that FHH.Pkhd1 rats had smaller and fewer renal collecting duct cysts compared with PCK rats (Fig.  1B ). These differences were significant at 30, 60, 90, and 120 days of age as assessed by a morphometrically derived semiquantitative CT-CI (P Ͻ 0.001 at all four time points) (Fig.  1C) . Differences in renal cyst size and abundance were most striking in younger animals, indicating that the FHH genetic background confers resistance to the development and progressive enlargement of renal cystic lesions of ARPKD.
Livers from FHH.Pkhd1 rats tended to be slightly smaller (36.22 g Ϯ 2.68) than livers from PCK rats (53.83 g Ϯ 8.08), but this difference was not significant at 27 wk of age ( Fig. 2A) . Bile duct dilatation together with selective fibrosis of portal areas defines the congenital hepatic fibrosis phenotype (35) . Liver fibrosis in the PCK and FHH.Pkhd1 occurs around virtually every cystic bile duct, and neither the PCK nor the FHH.Pkhd1 showed selective fibrosis (Fig. 2B) . Therefore, we quantified liver fibrosis as an overall estimation of liver damage. The degree of fibrosis was evaluated by morphometric determination of the percent of area fibrosis using Masson's Trichrome staining. At 120 days of age the percent of the left lobe that was fibrotic in the FHH.Pkhd1 livers was 21.30 Ϯ 5.6%. This was not significantly different from the percent of the left lobe of PN120 PCK male livers that was fibrotic (23.50 Ϯ 4.8%) (Fig. 2C) . Both PCK and FHH.Pkhd1 livers were significantly larger and had increased incidence of cyst formation compared with both SD and FHH livers (n ϭ 6, 12, 7, and 15 for SD, FHH, PCK, and FHH.Pkhd1 respectively). These data indicate that the protective genetic elements on the FHH background play a more pronounced role in renal cyst formation and growth than in biliary cyst formation.
Assessment of blood pressure and renal function in the FHH.Pkhd1 strain. Blood pressure increased with time in the PCK rat reaching 122 Ϯ 8 mmHg at 27 wk of age compared with the SD control, which remained relatively stable at 93 Ϯ 5 mmHg (P ϭ 0.007) (Fig. 3A) . Introgression of the Pkhd1 Fig. 1 . FHH.Pkhd1 rats have smaller kidneys and attenuated cyst formation compared with PCK rats. A: at 27 wk of age, kidneys from FHH.Pkhd1 rats are significantly smaller in weight than kidneys from PCK rats and not significantly larger than SD and FHH control kidneys. Number of animals was 6, 7, 12, and 15 for SD, PCK, FHH, and FHH.Pkdh1, respectively. B: H&E microscopic images taken with ϫ4 objective of PCK (1 and 3) and FHH.Pkhd1 (2 and 4) kidneys at postnatal day 30 (PN30) and postnatal day 90 (PN90). Bar indicates 100 M. C: renal cysts are smaller and less abundant in FHH.Pkhd1 kidneys compared with PCK kidneys at 30, 60, 90, and 120 days of age as quantified by collecting tubule cystic index (CTCI). Number of animals was 10 for both PCK and FHH.Pkhd1 at each time point. Data are presented as means Ϯ SE. ***P Ͻ 0.001. FHH, Fawn-Hooded Hypertensive; Pkhd1, polycystic kidney and hepatic disease 1 gene; PCK, polycystic kidney; SD, Sprague-Dawley; H&E, hematoxylin and eosin. Fig. 2 . FHH.Pkhd1 livers are not significantly protected from hepatic manifestations of the Pkhd1 mutation. A: at 27 wk of age FHH.Pkhd1 (n ϭ 15) livers are not significantly smaller than PCK livers (n ϭ 7). B: H&E stained liver sections (ϫ10 objective) from 120-day-old FHH.Pkhd1 and PCK rats demonstrate colocalization of fibrosis and biliary cysts. C: FHH.Pkhd1 (n ϭ 8) and PCK (n ϭ 8) showed no significant differences in percent area liver fibrosis as assessed by morphometric quantification. NS, not significant. locus from the PCK onto the FHH background did not induce changes in blood pressure compared with the control FHH strain (124 Ϯ 4 mmHg in FHH.Pkhd1 and 123 Ϯ 8 in FHH rats at 27 wk) (Fig. 3B) ; thus, blood pressure differences do not necessarily correlate with the presence of the Pkhd1 mutation.
PCK demonstrated significantly higher urinary protein excretion (UpV) (up to ϳ4-fold increase) than SD at 15, 24, and 27 wk of age (P Ͻ 0.001 at all time points), whereas FHH. Pkhd1 did not show a significant difference in UpV vs. FHH at any time point, although it had a tendency to be higher (Fig.  3C) . UpV of both the FHH.Pkhd1 and FHH was elevated compared with SD. The FHH rat is a spontaneous model of hypertension that ultimately results in progressive renal disease, and it is well documented that FHH rats excrete high levels of UpV. This did not significantly increase when the Pkhd1 mutation was introduced.
Plasma BUN (36.33 Ϯ 3.07) was elevated in PCK relative to FHH (20.50 Ϯ 3.22 mg/ml P Ͻ 0.001), SD (22.33 Ϯ 1.53 mg/ml, P ϭ 0.005), and FHH.Pkhd1 (25.89 Ϯ 3.59 mg/ml, P ϭ 0.019) (Fig. 3D) . PCK animals also demonstrated significantly higher plasma creatinine levels (0.80 Ϯ 0.10 mg/dl) compared with FHH (0.48 Ϯ 0.02 mg/dl, P Ͻ 0.001), SD (0.47 mg/dl Ϯ 0.03 P Ͻ 0.001) and FHH.Pkhd1 (0.542 Ϯ 0.05 mg/dl, P ϭ 0.002) (Fig. 3E) . FHH.Pkhd1 did not show a significant increase in BUN or plasma creatinine compared with either SD or FHH. Despite similar levels of proteinuria in both the PCK and FHH.Pkhd1 strains, renal function as assessed by BUN and plasma creatinine was clearly better in the FHH.Pkhd1 compared with PCK.
Detection of differentially expressed genes in PCK and FHH. Pkhd1 kidneys. RNA from kidneys of 30 day old SD, PCK, FHH and FHH.Pkhd1 rats was used for gene expression profiling. This time point was selected because the differences between PCK and FHH.Pkhd1 renal cyst formation was greatest at this time point. To account for expression differences that may depend solely on genomic background, gene expression of each cystic strain was compared with gene expression of the appropriate control strain. Thus, gene expression of PCK was compared with SD to determine differential expression of PCK genes, and gene expression of FHH.Pkhd1 was Fig. 3 . Blood pressure and renal impairment are elevated in PCK, but not FHH.Pkhd1, compared with respective control strains. Blood pressure was measured in awake rats by radiotelemetry starting at 11 wk through 27 wk of age. MAP, mean arterial pressure. A: PCK rats have significantly elevated blood pressure compared with SD control strain beginning at week 20, and blood pressure continues to increase through 27 wk of age. B: the FHH.Pkdh1 strain demonstrated no changes in blood pressure compared with the FHH control strain. Data is presented as means Ϯ SE. Number of animals is 6, 7, 6, and 8 for SD, FHH, PCK, and FHH.Pkdh1. C: 24 h proteinuria (UpV) measured at 15, 24, and 27 wk of age is elevated in PCK but not FHH.Pkhd1 compared with control. UpV is significantly higher in PCK compared with SD, whereas UpV is not significantly elevated in FHH.Pkhd1 compared with FHH. Both FHH and FHH.Pkhd1 excrete higher UpV compared with SD because FHH is a genetic model of progressive renal disease, and therefore this strain is proteinuric regardless of the Pkdh1 allele. Number of animals is 6, 6, 12, and 15 for SD, PCK, FHH, and FHH.Pkhd1, respectively. Data are presented as means Ϯ SE. D: at 27 wk of age FHH.Pkhd1 rats have attenuated azotemia compared with PCK rats. PCK rats have higher blood urea nitrogen (BUN) compared with FHH.Pkhd1, SD, and FHH, whereas FHH.Pkhd1 demonstrates no elevation in BUN. E: plasma creatinine is also elevated in the PCK compared with the 3 other strains. FHH.Pkhd1 plasma creatinine is not significantly higher than SD or FHH. Data are presented as means Ϯ SE. Number of animals is 6, 7, 6, and 9 for SD, FHH, PCK and FHH.Pkdh1, respectively. *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001. compared with FHH to determine differential expression of FHH.Pkhd1 genes.
Differentially expressed genes were divided into two categories: 1) genes up-or downregulated in PCK and not expressed in the same pattern in FHH.Pkhd1 were considered "uniquely misregulated" in PCK, 2) genes up-or downregulated in FHH.Pkhd1 and not expressed in the same pattern in PCK were considered "uniquely misregulated" in FHH.Pkhd1. We found 411 (231 up and 180 down) genes to be uniquely misregulated in PCK and 237 (132 up and 105 down) genes uniquely misregulated in FHH.Pkhd1. These gene lists were each interrogated by The Database for Annotation, Visualization and Integrated Discovery (20, 21) to determine biological processes that were uniquely modulated in each group (Table 3) .
Biological processes that were uniquely differentially expressed in PCK involved immunological processes, inflammation, and epithelial cell differentiation among others (Table  3A) . These networks fell into categories that correlate with disease pathways that have been previously described in human and rodent PKD (47) . As expected, PCK kidneys uniquely overexpressed some previously described expression markers of PKD such as Aqp3, Myc, Clu, Ren, laminins, and collagens (11) (12) (13) (14) 36) . FHH.Pkhd1 kidneys did not show upregulation of some biological processes common to PKD such as cell proliferation or inflammatory response (Table 3B ). Since the FHH.Pkhd1 animals were resistant to progression of renal cystic disease, genes uniquely expressed in this strain may play a role in protection from renal cystogenesis.
The most highly misregulated genes in PCK and FHH. Pkhd1 kidneys are listed in Table 4 . A small number of the genes found to be most differentially expressed in the PCK rat have been previously associated with renal cystogenesis (i.e., Alox15) (28), or renal damage (i.e., Kim1) (25) . Despite substantial expression differences in the PCK rat, many of the misregulated genes have not been linked to the pathophysiology of renal cyst formation or progressive enlargement before now.
We identified genes that were up-or downregulated in the same direction in both the FHH.Pkhd1 and PCK ("commonly misregulated") ( Table 5 ). Similar gene regulation in both PCK and FHH.Pkhd1 kidneys suggests that the expression of these genes may be in response to the Pkhd1 mutation itself and independent of to the severity of cystic disease. These genes that are misexpressed to a similar degree in PCK and FHH. Pkhd1 may provide insight into a number of unknown biological functions of fibrocystin. Several of the genes identified to be commonly misregulated in both ARPKD strains have been directly associated with renal function, or renal cysts before, [Cps1,(26) Areg (9, 39), and P2RY1 (19) ], but many of these genes have not been previously identified.
DISCUSSION
The genes responsible for both recessive and dominant forms of PKD have been identified (22, 32) . A handful of key molecular pathways have been associated with ARPKD cyst formation and progressive enlargement (47) ; however, the precise molecular mechanisms that govern disease pathogenesis remain unknown. Previous publications have documented that the genetic background influences the severity of monogenic diseases such as PKD in humans (41, 49), but identifying genetic modifiers in humans remains very difficult. Therefore, many groups have turned to genetic mapping of PKD modifiers in rodent models. To further facilitate the search for genes that modulate ARPKD disease progression and severity we created a novel congenic rat model by transferring the Pkhd1 allele from the PCK rat onto the FHH genetic background. Phenotypic analysis demonstrated that the newly developed FHH. Pkhd1 strain is resistant to renal cyst development and has improved renal function compared with the PCK rat.
FHH, FHH.Pkdh1, and PCK animals were all proteinuric, but the mechanism of UpV is not the same in these strains. Increased UpV in the PCK rat is due to the renal lesions resulting from the Pkhd1 mutation, whereas elevated UpV in the FHH and FHH.Pkhd1 results from the FHH genetic background. The FHH strain is a genetic model of renal failure, and these rats develop UpV and focal segmental glomerular sclerosis at a young age and eventually die of end-stage renal failure (7, 27, 29) . Thus, the cause of high UpV in the FHH and FHH.Pkhd1 is independent of the Pkdh1 mutation. Although the overall level of UpV is similar between PCK and FHH. Pkhd1, renal function is clearly improved in the FHH.Pkhd1 as indicated by BUN and plasma creatinine, and these measurements closely correlate with renal cyst formation.
While renal cyst formation was greatly diminished in the FHH.Pkhd1 animals, the FHH genetic background did not confer the same degree of protection against biliary manifestations and hepatic fibrosis. FHH.Pkdh1 livers tended to be smaller than PCK livers; however, this difference was not significant at 27 wk of age. The difference in protective effect of renal compared with biliary cystogenesis demonstrates that genetic elements on the FHH background specifically modulate kidney specific pathways. Therefore, the genes responsible for attenuated renal cyst formation in the FHH are likely kidney specific and not expressed in the liver.
Hypertension is a common feature of ARPKD in humans (13, 17) , but in the case of the FHH.Pkhd1, there was no increase in blood pressure over time. This could be because elevated blood pressure is secondary to kidney disease, and FHH.Pkhd1 had milder renal impairment than PCK. Alternatively, the absence of blood pressure elevations in the FHH. Pkhd1 could be attributed to a lack of renin angiotensin system (RAS) activation, which is thought to mediate the hypertension observed in PKD in humans (13, 31) as well as in the PCK rat (14, 23) . ACE and renin were both upregulated in PCK kidneys [1.47 (P ϭ 0.003)-and 1.61 (P Ͻ 0.001)-fold, respectively] compared with SD, but there was no major increase in ACE and a modest increase in renin gene expression in FHH.Pkhd1 compared with FHH [Ϫ1.03 (not significant)-and 1.15 (P Ͻ 0.001)-fold, respectively]. These expression results support the hypothesis that activation of the RAS may be responsible for, or at least contributing to, hypertension in the PCK rat.
Identifying molecules and pathways that modulate the progression of PKD can provide important targets for therapeutic intervention and may provide clues to disease severity. A number of studies have reported comprehensive transcriptional changes in PKD patients as well as murine models of PKD, which have led to the identification of numerous genes misregulated in cystic vs. healthy kidneys (11, 28, 36, 44, 46) . Although these studies provide insight into pathways that are modulated in PCK, it is unclear whether differentially expressed genes are directly involved in cyst formation as a result Continued of the Pkhd1 mutation or if expression differences are secondary to disease progression. By investigating mRNA expression in the PCK vs. SD and FHH.Pkhd1 vs. FHH, we were able to segregate genes and pathways that may be differentially expressed due to progression of cyst formation (PCK vs. SD) from those genes up-or downregulated in response to the Pkhd1 mutation itself (genes common in PCK vs. SD and FHH.Pkhd1 vs. FHH), independent of the state of disease progression. Not surprisingly, we found a number of genes previously described to be differentially expressed in murine and human cystic kidneys to also be differentially expressed in PCK kidneys but not FHH.Pkhd1 kidneys. The altered expression of these genes correlates with the severity of renal cystogenesis, suggesting that regulation of many genes associated with PKD is due to secondary phenotypic differences (i.e., state of disease progression) and are not directly modulated by the Pkhd1 mutation. Inflammatory and immune response as well as epithelial growth and cell proliferation were major biological processes activated in PCK kidneys, which have been previously described in cystic kidneys (11, 28, 44, 46) .
The transcriptional analysis of both PCK and FHH.Pkhd1 revealed genes that may be directly regulated by the Pkhd1 mutation, as they were differentially expressed to a similar degree in both FHH.Pkhd1 and PCK. Pcdh9 (Protocadherin 9) was similarly downregulated in both FHH.Pkdh1 (Ϫ2.8-fold) 2), or expressed in the opposite direction in FHH.Pkhd1 were considered "uniquely misregulated" in PCK and uploaded into to identify enriched biological processes (BP) to generate part A. B: genes up-or downregulated in FHH.Pkhd1 (Ͼ1.45 of ϽϪ1.45-fold) and not differentially expressed (Ͻ1.2 or Ͼ Ϫ1.2), or expressed in the opposite direction in PCK were considered "uniquely misregulated" in FHH.Pkhd1 and uploaded into DAVID to identify enriched biological processes for part B. Gene ontology (GO) identifiers are listed in the lefthand column. Count indicates the number of molecules from the gene list in each BP, % is the percent of molecules out of the whole gene list that fell into each BP.
and PCK (Ϫ3.5-fold) compared with control strains, suggesting that the expression of this gene is directly associated with the Pkhd1 mutation itself and may be involved in pathways downstream of fibrocystin. Little is known about Pcdh9, but it has been demonstrated that knock-down of protocadherin family members Fat4 and Fat1 result in renal cyst formation in mice and zebrafish, respectively (43, 45) . These studies demonstrate that certain protocadherins are necessary for normal renal epithelial arrangement. The similar downregulation of Pcdh9 in PCK and FHH.Pkhd1 kidneys along with evidence that protocadherin knockdown causes renal cyst formation suggests that Pcdh9 expression may be directly influenced by the fibrocystin mutation. Molecules up-or downregulated in the same direction in both PCK and FHH.Pkhd1, but to a very different degree (i.e., Cps1, Ugt2B15, and Slco1a1) could be misregulated due to secondary phenotypic effects and not directly influenced by the Pkhd1 mutation, since the degree of regulation appears to be independent of the presence of the Pkhd1 mutation. However, further studies are required to address this hypothesis. The microarray analysis carried out in the present study is a powerful comparison because we identified molecules and pathways that are associated with the cystic phenotype of ARPKD as well as molecules that may be directly modulated by the Pkhd1 mutation. In summary, the newly developed FHH.Pkhd1 rat strain has attenuated susceptibility to renal cystogenesis and insufficiency compared with PCK rats even though both strains carry the same Pkhd1 mutant allele. In future studies, the FHH.Pkhd1 and PCK strains can be used to identify genetic modifiers of ARPKD aggression by consomic mapping and F2 linkage analysis. Molecules and pathways found to influence ARPKD susceptibility can provide therapeutic targets for treating ARPKD, and can aid in treating and predicting outcomes of this devastating disease.
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